Evaluation of Vitamin A and E Deficiency With Severity of SARS-COV-2 Disease: A Case-Control Study
Correlation Between Vitamin A and E Deficiency With Severity of SARS-COV2 Disease.
1 other identifier
observational
90
1 country
1
Brief Summary
Coronavirus disease 2019 (COVID-19) is a novel infectious disease that has been spreading worldwide Coronaviridae study group of the International Committee on taxonomy of viruses (2020). The clinical manifestation of COVID-19 can range from asymptomatic infection to critical illness with severe pneumonia, respiratory failure, and death. Vitamin A is of special interest in the field of infectious diseases, especially for pulmonary infections. It is crucial for the development of normal lung tissue and tissue repair after injury due to infection. Therefore, it may play a role in recovery after severe COVID-19 pneumonia. Vitamin A has immune regulatory functions and positively affects both the innate and adaptive immune cell response. The anti-oxidant Vitamin E, and trace element selenium, are major components of anti-oxidant defense. Epidemiological studies demonstrate that deficiencies in, either of these nutrients, alters immune responses and viral pathogenicity. Data concerning vitamin A and E plasma levels in COVID-19 patients are lacking. Therefore, this study aims at characterizing vitamin A and E plasma levels in COVID-19 and analyzing the association of plasma levels with disease severity and outcome.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Sep 2021
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 30, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
May 30, 2022
CompletedFirst Submitted
Initial submission to the registry
July 12, 2023
CompletedFirst Posted
Study publicly available on registry
July 14, 2023
CompletedAugust 22, 2023
August 1, 2023
8 months
July 12, 2023
August 18, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Correlating between vitamin A and E deficiency and severity of SARS-COV2
Evaluation of vitamin A and E deficiency with COVID-19 disease severity
From September 2021 to November 2022
Study Arms (3)
Group A
30 ICU-admitted SARS-CoV-2- infected individuals with ARDS or in need of oxygen supplementation
Group B
30 ward-admitted SARS-CoV-2-infected individuals not suffering from ARDS and not in need of oxygen supplementation
Group C
30 sex and age-matched normal individuals
Eligibility Criteria
COVID=19 patients recruited from ICU (intensive care Unit) and chest ward
You may qualify if:
- COVID-19 positive patients by PCR (polymerase chain reaction) test
- Patients aging 18 to 75 years
You may not qualify if:
- Patients with known immunodeficiency - Patients with known lung diseases
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Cairo Universitylead
Study Sites (1)
balsam Sherif Fahmy
Cairo, None Selected, 11511, Egypt
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Lecturer
Study Record Dates
First Submitted
July 12, 2023
First Posted
July 14, 2023
Study Start
September 1, 2021
Primary Completion
April 30, 2022
Study Completion
May 30, 2022
Last Updated
August 22, 2023
Record last verified: 2023-08